• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

CG Oncology, Inc. - Common stock (NQ: CGON )

28.67 +0.65 (+2.32%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,470,755
Open 27.58
Bid (Size) 27.26 (1)
Ask (Size) 29.90 (1)
Prev. Close 28.02
Today's Range 27.58 - 28.94
52wk Range 25.77 - 50.23
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
CG Oncology Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
December 16, 2024
From CG Oncology Inc.
Via GlobeNewswire
CG Oncology Announces Pricing of Public Offering
December 12, 2024
From CG Oncology Inc.
Via GlobeNewswire

Performance

YTD
-27.69%
-27.69%
1 Month
-11.35%
-11.35%
3 Month
-25.22%
-25.22%
6 Month
-10.13%
-10.13%
1 Year
-27.69%
-27.69%

More News

Read More
Why CG Oncology (CGON) Stock Is Down 9%
December 11, 2024
Via Benzinga
Demystifying CG Oncology: Insights From 7 Analyst Reviews
December 06, 2024
Via Benzinga
A Closer Look at 9 Analyst Recommendations For CG Oncology
June 28, 2024
Via Benzinga
Decoding 10 Analyst Evaluations For CG Oncology
May 14, 2024
Via Benzinga
Nasdaq Jumps 300 Points To Record Highs
December 11, 2024
Via Talk Markets
Topics Stocks / Equities
CG Oncology Announces Proposed Public Offering
December 11, 2024
From CG Oncology Inc.
Via GlobeNewswire
SUO-CTC and CG Oncology Announce the First Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award
December 06, 2024
From CG Oncology Inc.
Via GlobeNewswire
CG Oncology Touts Encouraging Data From Late-Stage Study Of Bladder Cancer Candidate
December 05, 2024
Via Benzinga
Groundbreaking Cretostimogene Grenadenorepvec Monotherapy Data Demonstrates Sustained, Durable Complete Responses in High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
December 05, 2024
From CG Oncology Inc.
Via GlobeNewswire
CG Oncology to Host Conference Call and Webcast on BOND-003 Data on Thursday, December 5, 2024
December 02, 2024
From CG Oncology Inc.
Via GlobeNewswire
CG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 25th Annual Meeting
November 20, 2024
From CG Oncology Inc.
Via GlobeNewswire
CG Oncology Reports Third Quarter 2024 Financial Results and Provides Business Updates
November 12, 2024
From CG Oncology Inc.
Via GlobeNewswire
CG Oncology Announces Nature Medicine Publication of Phase 1b Study Results Evaluating Cretostimogene Grenadenorepvec in Combination with Nivolumab in Muscle-Invasive Bladder Cancer
November 11, 2024
From CG Oncology Inc.
Via GlobeNewswire
Discover the 3 Best-Performing Biotech IPO Stocks of 2024
November 06, 2024
Via MarketBeat
Topics Initial Public Offering
Exposures Securities Market
This Sempra Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
October 24, 2024
Via Benzinga
CG Oncology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
August 30, 2024
From CG Oncology Inc.
Via GlobeNewswire
CGON Stock Earnings: CG Oncology Beats EPS for Q2 2024
August 08, 2024
Via InvestorPlace
CG Oncology Reports Second Quarter 2024 Financial Results and Provides Business Updates
August 08, 2024
From CG Oncology Inc.
Via GlobeNewswire
CG Oncology Initiates Expanded Access Program for Cretostimogene Grenadenorepvec
June 18, 2024
From CG Oncology Inc.
Via GlobeNewswire
CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive NMIBC
June 06, 2024
From CG Oncology Inc.
Via GlobeNewswire
Why Science Applications International Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Monday's Mid-Day Session
June 03, 2024
Via Benzinga
Stericycle, MarineMax, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Monday
June 03, 2024
Via Benzinga
CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive High-Risk NMIBC at ASCO 2024 Annual Meeting
May 24, 2024
From CG Oncology Inc.
Via GlobeNewswire
Site Logo
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap